NASDAQ:TENX - Tenax Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 135.85 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.12
▲ +0.02 (0.95%)
1 month | 3 months | 12 months
Get New Tenax Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TENX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TENX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +135.85% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Tenax Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 135.85% upside from the last price of $2.12.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Tenax Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2020HC WainwrightInitiated CoverageBuy$5.00N/A
i
Rating by V. Bernardino at HC Wainwright
5/18/2017LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$50.00High
i
(Data available from 3/8/2016 forward)
Tenax Therapeutics logo
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $2.12
$2.06
$2.29

50 Day Range

MA: $2.37
$1.78
$2.79

52 Week Range

Now: $2.12
$0.25
$3.68

Volume

248,089 shs

Average Volume

1,948,022 shs

Market Capitalization

$26.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Tenax Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Tenax Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for TENX.

What is the current price target for Tenax Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Tenax Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 135.8%. HC Wainwright has the highest price target set, predicting TENX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Tenax Therapeutics in the next year.
View the latest price targets for TENX.

What is the current consensus analyst rating for Tenax Therapeutics?

Tenax Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TENX will outperform the market and that investors should add to their positions of Tenax Therapeutics.
View the latest ratings for TENX.

What other companies compete with Tenax Therapeutics?

How do I contact Tenax Therapeutics' investor relations team?

Tenax Therapeutics' physical mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company's listed phone number is 919-855-2100 and its investor relations email address is [email protected] The official website for Tenax Therapeutics is www.tenaxthera.com.